Xvivo Perfusion Q3: Continued strong growth for warm perfusion
Sales in Q3 came in lower than expected, but sales related to warm perfusion were in line with our forecast and saw continued strong growth. The gross margin for non-durable goods was in line with our expectations, but slightly higher-than-expected operating expenses and depreciation resulted in an EBIT margin below our forecast. Overall, we keep a positive view on the report, focusing on the strong result for sales related to warm perfusion. We will return with an updated analysis shortly.